Profile - To The Moon

HauSG

Posts · 34Posts · 34
Following · 0Following · 0
Followers · 0Followers · 0

- HauSGHauSG
  ·2021-09-16
  Potential stock
  229 Comment
  Like
  Share
  Report
- HauSGHauSG
  ·2021-09-07
  Temporary effect
  Hyundai Sees a Bright Future for Hydrogen by 2040
  New buses and trucks to run on batteries, fuel cells by 2028. Group unveils future mobility solution
  Hyundai Sees a Bright Future for Hydrogen by 2040
  252 Comment
  Like
  Share
  Report
- HauSGHauSG
  ·2021-09-07
  I look well this
  206 Comment
  Like
  Share
  Report
- HauSGHauSG
  ·2021-09-03
  Covid pls stop
  AstraZeneca reaches settlement with EU on COVID-19 vaccine delivery
  Sept 3 (Reuters) - AstraZeneca and the European Commission and have reached a settlement on the deli
  AstraZeneca reaches settlement with EU on COVID-19 vaccine delivery
  294 1
  3
  Share
  Report
- HauSGHauSG
  ·2021-09-03
  Pfizer will up
  Here's the Biotech Pfizer Should Consider Acquiring Next
  This under-the-radar immunotherapy maker would bring a lot to the table for Pfizer.
  Here's the Biotech Pfizer Should Consider Acquiring Next
  405 1
  7
  Share
  Report
- HauSGHauSG
  ·2021-09-03
  Today no movement
  150 Comment
  Like
  Share
  Report
- HauSGHauSG
  ·2021-09-03
  Cfm can invest
  136 Comment
  Like
  Share
  Report
- HauSGHauSG
  ·2021-09-02
  I will buy
  U.S. manufacturing activity rises; shortages linger
  Summary ISM manufacturing index rises 0.4 pts to 59.9 in August. New orders measure increases; empl
  U.S. manufacturing activity rises; shortages linger
  226 Comment
  4
  Share
  Report
- HauSGHauSG
  ·2021-09-02
  No surprise today
  277 Comment
  Like
  Share
  Report
- HauSGHauSG
  ·2021-09-02
  Nice story
  Tech stocks send Nasdaq to fresh record close, boost S&P
  Gains for tech stocks, utilities and real estate. August private jobs growth misses expectations. In
  Tech stocks send Nasdaq to fresh record close, boost S&P
  408 Comment
  3
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3582448988391909","uuid":"3582448988391909","gmtCreate":1619354964440,"gmtModify":1704447497561,"name":"HauSG","pinyin":"hausg","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":39,"tweetSize":34,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.19","exceedPercentage":"60.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":885155036,"gmtCreate":1631768679425,"gmtModify":1676530630807,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"Potential stock&nbsp;","listText":"Potential stock&nbsp;","text":"Potential stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885155036","isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880967944,"gmtCreate":1631011260188,"gmtModify":1676530441629,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"Temporary&nbsp; effect&nbsp;","listText":"Temporary&nbsp; effect&nbsp;","text":"Temporary effect","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880967944","repostId":"1187871270","repostType":4,"repost":{"id":"1187871270","pubTimestamp":1630998861,"share":"https://ttm.financial/m/news/1187871270?lang=&edition=fundamental","pubTime":"2021-09-07 15:14","market":"us","language":"en","title":"Hyundai Sees a Bright Future for Hydrogen by 2040","url":"https://stock-news.laohu8.com/highlight/detail?id=1187871270","media":"Bloomberg","summary":"New buses and trucks to run on batteries, fuel cells by 2028.\nGroup unveils future mobility solution","content":"<ul>\n <li>New buses and trucks to run on batteries, fuel cells by 2028.</li>\n <li>Group unveils future mobility solutions using hydrogen.</li>\n</ul>\n<p>The Hyundai Motor Group unveiled plans to roll out hydrogen-based technology and mobility solutions for transport and other industrial sectors by 2040 as many countries aim to become carbon neutral by the middle of this century.</p>\n<p>South Korea’s second-biggest conglomerate aims to have all of its new commercial vehicles, such as buses and heavy-duty trucks, run on either batteries or fuel cells by 2028, becoming the world’s first automaker to do so, Group Chairman Euisun Chung said Tuesday at the company’s first day to showcase its hydrogen technology to investors. It’s also working on some concept hydrogen mobility solutions that could be used at ports, on rescue missions and trams.</p>\n<p>“Our goal is to introduce a wide range of hydrogen-based mobility solutions by 2040,” Chung said. “This will include passenger cars, special vehicles, trains, ships and urban air mobility. We also want to expand the use of hydrogen fuel cells in different areas including robots and eco-friendly generators.”</p>\n<p>Hyundai Motor Co.is seeking to become carbon neutral by 2045 by phasing out vehicles using fossil fuels in major markets by 2040. The parent conglomerate has been investing in hydrogen fuel cell vehicles and systems, with its first model introduced in 2013. It became the first manufacturer to commercialize heavy-duty trucks last year.</p>\n<p>The group plans to introduce its new fuel-celled passenger vehicle in 2023 and a large sport-utility vehicle in 2025. It also plans to sell a tractor, which is currently in trial in California, in 2023. Hyundai Motor, the country’s biggest automaker, sold 5,300 fuel cell vehicles in the first seven months of this year to grab 51% of the global market, according to&nbsp;SNE Research.</p>\n<p>Hyundai Motor has already unveiled some concept mobility solutions that run on fuel cells. The trailer drone is an autonomous hydrogen-powered container transportation system, which has a range of more than 1,000 kilometers on a single charge and can turn sideways. The rescue drone can be operated remotely for fire-fighting and life-saving missions and has the capability to move sideways, or “crab-walk.”</p>\n<p>The group also plans to provide its fuel cell solutions to the energy sector, including electricity and heating for buildings, urban energy sources and power plants.</p>\n<p>“We strongly believe that both battery and fuel-cell technologies and products are needed to make the transition to zero emission mobility,” Chung said. “Fighting climate change and shifting to renewable energy will not be complete without hydrogen.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hyundai Sees a Bright Future for Hydrogen by 2040</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHyundai Sees a Bright Future for Hydrogen by 2040\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 15:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-09-07/hyundai-sees-a-bright-future-for-hydrogen-applications-by-2040?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New buses and trucks to run on batteries, fuel cells by 2028.\nGroup unveils future mobility solutions using hydrogen.\n\nThe Hyundai Motor Group unveiled plans to roll out hydrogen-based technology and ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-07/hyundai-sees-a-bright-future-for-hydrogen-applications-by-2040?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HYUD.UK":"现代汽车"},"source_url":"https://www.bloomberg.com/news/articles/2021-09-07/hyundai-sees-a-bright-future-for-hydrogen-applications-by-2040?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187871270","content_text":"New buses and trucks to run on batteries, fuel cells by 2028.\nGroup unveils future mobility solutions using hydrogen.\n\nThe Hyundai Motor Group unveiled plans to roll out hydrogen-based technology and mobility solutions for transport and other industrial sectors by 2040 as many countries aim to become carbon neutral by the middle of this century.\nSouth Korea’s second-biggest conglomerate aims to have all of its new commercial vehicles, such as buses and heavy-duty trucks, run on either batteries or fuel cells by 2028, becoming the world’s first automaker to do so, Group Chairman Euisun Chung said Tuesday at the company’s first day to showcase its hydrogen technology to investors. It’s also working on some concept hydrogen mobility solutions that could be used at ports, on rescue missions and trams.\n“Our goal is to introduce a wide range of hydrogen-based mobility solutions by 2040,” Chung said. “This will include passenger cars, special vehicles, trains, ships and urban air mobility. We also want to expand the use of hydrogen fuel cells in different areas including robots and eco-friendly generators.”\nHyundai Motor Co.is seeking to become carbon neutral by 2045 by phasing out vehicles using fossil fuels in major markets by 2040. The parent conglomerate has been investing in hydrogen fuel cell vehicles and systems, with its first model introduced in 2013. It became the first manufacturer to commercialize heavy-duty trucks last year.\nThe group plans to introduce its new fuel-celled passenger vehicle in 2023 and a large sport-utility vehicle in 2025. It also plans to sell a tractor, which is currently in trial in California, in 2023. Hyundai Motor, the country’s biggest automaker, sold 5,300 fuel cell vehicles in the first seven months of this year to grab 51% of the global market, according to SNE Research.\nHyundai Motor has already unveiled some concept mobility solutions that run on fuel cells. The trailer drone is an autonomous hydrogen-powered container transportation system, which has a range of more than 1,000 kilometers on a single charge and can turn sideways. The rescue drone can be operated remotely for fire-fighting and life-saving missions and has the capability to move sideways, or “crab-walk.”\nThe group also plans to provide its fuel cell solutions to the energy sector, including electricity and heating for buildings, urban energy sources and power plants.\n“We strongly believe that both battery and fuel-cell technologies and products are needed to make the transition to zero emission mobility,” Chung said. “Fighting climate change and shifting to renewable energy will not be complete without hydrogen.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880964636,"gmtCreate":1631011227325,"gmtModify":1676530441607,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"I look well this","listText":"I look well this","text":"I look well this","images":[{"img":"https://static.tigerbbs.com/3ed9f1b17e5ac27c799ecb3f7c2feb5b","width":"720","height":"1541"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880964636","isVote":1,"tweetType":1,"viewCount":206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815861431,"gmtCreate":1630666939023,"gmtModify":1676530370693,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"Covid pls stop","listText":"Covid pls stop","text":"Covid pls stop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/815861431","repostId":"2164876904","repostType":4,"repost":{"id":"2164876904","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630663092,"share":"https://ttm.financial/m/news/2164876904?lang=&edition=fundamental","pubTime":"2021-09-03 17:58","market":"us","language":"en","title":"AstraZeneca reaches settlement with EU on COVID-19 vaccine delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2164876904","media":"Reuters","summary":"Sept 3 (Reuters) - AstraZeneca and the European Commission and have reached a settlement on the deli","content":"<p>Sept 3 (Reuters) - AstraZeneca&nbsp;and the European Commission and have reached a settlement on the delivery of pending COVID-19 vaccine doses by the drugmaker, ending a row about shortages that had weighed on the company and the region's vaccination campaign.</p>\n<p>The dispute plunged the European Union into crisis earlier this year as states, under pressure to speed up vaccinations, scrambled for shots. It also caused a public relations crisis for AstraZeneca, which is led by Frenchman Pascal Soriot.</p>\n<p>Brussels has since reduced its reliance on the Anglo-Swedish drugmaker, with vaccine supplies coming from Pfizer/BioNTech, Moderna and Johnson &amp; Johnson.</p>\n<p>Under Friday's settlement</p>\n<p>AstraZeneca has committed to deliver 60 million doses of its vaccine, Vaxzevria, by the end of the third quarter this year, 75 million by the end of the fourth quarter and 65 million by the end of the first quarter of 2022.</p>\n<p>The European Commission launched legal action against AstraZeneca in April</p>\n<p>for not respecting its contract for the supply of COVID-19 vaccines and for not having a \"reliable\" plan to ensure timely deliveries.</p>\n<p>The EU's executive body said</p>\n<p>that under the new agreement, member states would be provided with regular delivery schedules and if there were any delayed doses, capped rebates would be applied.</p>\n<p>VACCINATION RATES</p>\n<p>\"There are significant differences in vaccination rates between our member states, and the continued availability of vaccines, including AstraZeneca's, remain crucial,\" said EU Commissioner for Health and Food Safety Stella Kyriakides.</p>\n<p>The EU settlement allows for distribution while the highly-contagious Delta variant of the coronavirus is causing a spike in cases and vaccines are being studied for longevity of protection.</p>\n<p>\"I'm very pleased that we have been able to reach a common understanding which allows us to move forward and work in collaboration with the European Commission to help overcome the pandemic,\" said AstraZeneca senior executive Ruud Dobber.</p>\n<p>The European Commission said this week that 70% of the European Union's adult population had been fully vaccinated against COVID-19, hitting a target it set at the beginning of the year.</p>\n<p>About 92 million doses of AstraZeneca's vaccine have been distributed to EU member states so far, according to the European Centre for Disease Prevention and Control. That is far below the 437 million doses delivered by Pfizer/BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca reaches settlement with EU on COVID-19 vaccine delivery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca reaches settlement with EU on COVID-19 vaccine delivery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-03 17:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 3 (Reuters) - AstraZeneca&nbsp;and the European Commission and have reached a settlement on the delivery of pending COVID-19 vaccine doses by the drugmaker, ending a row about shortages that had weighed on the company and the region's vaccination campaign.</p>\n<p>The dispute plunged the European Union into crisis earlier this year as states, under pressure to speed up vaccinations, scrambled for shots. It also caused a public relations crisis for AstraZeneca, which is led by Frenchman Pascal Soriot.</p>\n<p>Brussels has since reduced its reliance on the Anglo-Swedish drugmaker, with vaccine supplies coming from Pfizer/BioNTech, Moderna and Johnson &amp; Johnson.</p>\n<p>Under Friday's settlement</p>\n<p>AstraZeneca has committed to deliver 60 million doses of its vaccine, Vaxzevria, by the end of the third quarter this year, 75 million by the end of the fourth quarter and 65 million by the end of the first quarter of 2022.</p>\n<p>The European Commission launched legal action against AstraZeneca in April</p>\n<p>for not respecting its contract for the supply of COVID-19 vaccines and for not having a \"reliable\" plan to ensure timely deliveries.</p>\n<p>The EU's executive body said</p>\n<p>that under the new agreement, member states would be provided with regular delivery schedules and if there were any delayed doses, capped rebates would be applied.</p>\n<p>VACCINATION RATES</p>\n<p>\"There are significant differences in vaccination rates between our member states, and the continued availability of vaccines, including AstraZeneca's, remain crucial,\" said EU Commissioner for Health and Food Safety Stella Kyriakides.</p>\n<p>The EU settlement allows for distribution while the highly-contagious Delta variant of the coronavirus is causing a spike in cases and vaccines are being studied for longevity of protection.</p>\n<p>\"I'm very pleased that we have been able to reach a common understanding which allows us to move forward and work in collaboration with the European Commission to help overcome the pandemic,\" said AstraZeneca senior executive Ruud Dobber.</p>\n<p>The European Commission said this week that 70% of the European Union's adult population had been fully vaccinated against COVID-19, hitting a target it set at the beginning of the year.</p>\n<p>About 92 million doses of AstraZeneca's vaccine have been distributed to EU member states so far, according to the European Centre for Disease Prevention and Control. That is far below the 437 million doses delivered by Pfizer/BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","AZN":"阿斯利康","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164876904","content_text":"Sept 3 (Reuters) - AstraZeneca and the European Commission and have reached a settlement on the delivery of pending COVID-19 vaccine doses by the drugmaker, ending a row about shortages that had weighed on the company and the region's vaccination campaign.\nThe dispute plunged the European Union into crisis earlier this year as states, under pressure to speed up vaccinations, scrambled for shots. It also caused a public relations crisis for AstraZeneca, which is led by Frenchman Pascal Soriot.\nBrussels has since reduced its reliance on the Anglo-Swedish drugmaker, with vaccine supplies coming from Pfizer/BioNTech, Moderna and Johnson & Johnson.\nUnder Friday's settlement\nAstraZeneca has committed to deliver 60 million doses of its vaccine, Vaxzevria, by the end of the third quarter this year, 75 million by the end of the fourth quarter and 65 million by the end of the first quarter of 2022.\nThe European Commission launched legal action against AstraZeneca in April\nfor not respecting its contract for the supply of COVID-19 vaccines and for not having a \"reliable\" plan to ensure timely deliveries.\nThe EU's executive body said\nthat under the new agreement, member states would be provided with regular delivery schedules and if there were any delayed doses, capped rebates would be applied.\nVACCINATION RATES\n\"There are significant differences in vaccination rates between our member states, and the continued availability of vaccines, including AstraZeneca's, remain crucial,\" said EU Commissioner for Health and Food Safety Stella Kyriakides.\nThe EU settlement allows for distribution while the highly-contagious Delta variant of the coronavirus is causing a spike in cases and vaccines are being studied for longevity of protection.\n\"I'm very pleased that we have been able to reach a common understanding which allows us to move forward and work in collaboration with the European Commission to help overcome the pandemic,\" said AstraZeneca senior executive Ruud Dobber.\nThe European Commission said this week that 70% of the European Union's adult population had been fully vaccinated against COVID-19, hitting a target it set at the beginning of the year.\nAbout 92 million doses of AstraZeneca's vaccine have been distributed to EU member states so far, according to the European Centre for Disease Prevention and Control. That is far below the 437 million doses delivered by Pfizer/BioNTech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815880658,"gmtCreate":1630665507374,"gmtModify":1676530370270,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"Pfizer will up","listText":"Pfizer will up","text":"Pfizer will up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/815880658","repostId":"2164876424","repostType":4,"repost":{"id":"2164876424","pubTimestamp":1630662600,"share":"https://ttm.financial/m/news/2164876424?lang=&edition=fundamental","pubTime":"2021-09-03 17:50","market":"us","language":"en","title":"Here's the Biotech Pfizer Should Consider Acquiring Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2164876424","media":"Motley Fool","summary":"This under-the-radar immunotherapy maker would bring a lot to the table for Pfizer.","content":"<p>Kudos to&nbsp;<b>Pfizer</b> (NYSE:PFE) for its decision to acquire <b>Trillium Therapeutics</b> (NASDAQ:TRIL). The small biotech's cancer pipeline is a great fit for Pfizer. Trillium's candidates could begin contributing to Pfizer's growth in the second half of the decade, just when the big drugmaker will need a boost due to patent expirations for several of its top drugs.</p>\n<p>The price tag of the transaction is close to $2.3 billion. That leaves Pfizer with a huge amount of cash that it could use in making more deals. There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> biotech in particular that I think Pfizer should consider acquiring next.</p>\n<h2>Going solo doesn't rule out getting some help</h2>\n<p>Pfizer and its partner <b>BioNTech</b> (NASDAQ:BNTX) achieved remarkable success with their messenger RNA (mRNA) vaccine Comirnaty (BNT162b2). The companies continue to work together on developing mRNA COVID-19 vaccines that are effective against emerging coronavirus variants. They're also collaborating on an mRNA flu vaccine program.</p>\n<p>However, Pfizer CEO Albert Bourla revealed in a March 2021 interview with <i>The Wall Street Journal</i> that his company plans to move forward on its own with additional mRNA programs. Bourla said Pfizer is \"the best-positioned company right now to take [mRNA technology] to the next step because of our size and our expertise.\"</p>\n<p>There's no doubt that Pfizer's team did gain quite a bit of expertise with its work alongside BioNTech's scientists. Still, though, I suspect that the big pharma company wouldn't hesitate to build up that expertise even more, and gain promising mRNA technology at the same time.</p>\n<p>That's why I think that Pfizer could be the ideal suitor for&nbsp;<b>Gritstone Bio</b> (NASDAQ:GRTS). It's understandable why Pfizer might be reluctant to buy BioNTech, with the German biotech's market cap near $80 billion. But Gritstone's market cap remains below $500 million. Pfizer could practically acquire the up-and-coming biotech with its spare change.</p>\n<h2>mRNA and more</h2>\n<p>Gritstone is developing its own COVID vaccine candidate that's expected to advance into early-stage clinical testing this year. But the biotech doesn't employ the ordinary mRNA approach that's used with Pfizer's Comirnaty. Gritstone's experimental vaccine uses a viral vector for the prime dose following by a self-amplifying mRNA (SAM) vector for the boost. The company believes this method could provide better protection against emerging variants than first-generation vaccines such as Comirnaty.</p>\n<p>The small biotech brings more than just this promising mRNA technology to the table, though. Gritstone's Edge technology uses neural networks to predict which mutations will generate antigens most likely to be present on cell surfaces of viruses and tumors. The company then delivers those specific antigens using its viral prime/SAM boost vaccines.</p>\n<p>Gritstone already has a couple of pipeline programs in phase 2 testing. Granite is an individualized immunotherapy targeting solid tumors including metastatic microsatellite stable colorectal cancer (MSS-CRC), gastroesophageal cancer, and non-small cell lung cancer (NSCLC). Slate is an \"off the shelf\" immunotherapy targeting solid tumors with select KRAS mutations.</p>\n<p>If Pfizer acquired Gritstone, the company would pick up two promising cancer immunotherapy candidates. It would gain a COVID vaccine candidate that could be ideal for battling emerging variants. The company would also add a platform that could enable it to more effectively develop a stable of new drugs targeting a variety of diseases.</p>\n<h2>Bigger targets in sight?</h2>\n<p>It's entirely possible that Pfizer could choose to buy a much larger drugmaker that would immediately boost its revenue and earnings. The company could afford to do so with its fast-growing cash stockpile.</p>\n<p>But my view is that deals along the lines of the Trillium acquisition are a better use of Pfizer's money. The company should be able to deliver strong growth at least through 2025. Spending less now to gobble up smaller biotechs that could pay off after that point appears to be a smart game plan.</p>\n<p>I think an acquisition of Gritstone by Pfizer could fit quite nicely with such a strategy. And it could make the big pharma stock a bigger winner over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's the Biotech Pfizer Should Consider Acquiring Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's the Biotech Pfizer Should Consider Acquiring Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 17:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/03/heres-the-biotech-pfizer-should-consider-acquiring/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kudos to Pfizer (NYSE:PFE) for its decision to acquire Trillium Therapeutics (NASDAQ:TRIL). The small biotech's cancer pipeline is a great fit for Pfizer. Trillium's candidates could begin ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/03/heres-the-biotech-pfizer-should-consider-acquiring/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/03/heres-the-biotech-pfizer-should-consider-acquiring/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164876424","content_text":"Kudos to Pfizer (NYSE:PFE) for its decision to acquire Trillium Therapeutics (NASDAQ:TRIL). The small biotech's cancer pipeline is a great fit for Pfizer. Trillium's candidates could begin contributing to Pfizer's growth in the second half of the decade, just when the big drugmaker will need a boost due to patent expirations for several of its top drugs.\nThe price tag of the transaction is close to $2.3 billion. That leaves Pfizer with a huge amount of cash that it could use in making more deals. There's one biotech in particular that I think Pfizer should consider acquiring next.\nGoing solo doesn't rule out getting some help\nPfizer and its partner BioNTech (NASDAQ:BNTX) achieved remarkable success with their messenger RNA (mRNA) vaccine Comirnaty (BNT162b2). The companies continue to work together on developing mRNA COVID-19 vaccines that are effective against emerging coronavirus variants. They're also collaborating on an mRNA flu vaccine program.\nHowever, Pfizer CEO Albert Bourla revealed in a March 2021 interview with The Wall Street Journal that his company plans to move forward on its own with additional mRNA programs. Bourla said Pfizer is \"the best-positioned company right now to take [mRNA technology] to the next step because of our size and our expertise.\"\nThere's no doubt that Pfizer's team did gain quite a bit of expertise with its work alongside BioNTech's scientists. Still, though, I suspect that the big pharma company wouldn't hesitate to build up that expertise even more, and gain promising mRNA technology at the same time.\nThat's why I think that Pfizer could be the ideal suitor for Gritstone Bio (NASDAQ:GRTS). It's understandable why Pfizer might be reluctant to buy BioNTech, with the German biotech's market cap near $80 billion. But Gritstone's market cap remains below $500 million. Pfizer could practically acquire the up-and-coming biotech with its spare change.\nmRNA and more\nGritstone is developing its own COVID vaccine candidate that's expected to advance into early-stage clinical testing this year. But the biotech doesn't employ the ordinary mRNA approach that's used with Pfizer's Comirnaty. Gritstone's experimental vaccine uses a viral vector for the prime dose following by a self-amplifying mRNA (SAM) vector for the boost. The company believes this method could provide better protection against emerging variants than first-generation vaccines such as Comirnaty.\nThe small biotech brings more than just this promising mRNA technology to the table, though. Gritstone's Edge technology uses neural networks to predict which mutations will generate antigens most likely to be present on cell surfaces of viruses and tumors. The company then delivers those specific antigens using its viral prime/SAM boost vaccines.\nGritstone already has a couple of pipeline programs in phase 2 testing. Granite is an individualized immunotherapy targeting solid tumors including metastatic microsatellite stable colorectal cancer (MSS-CRC), gastroesophageal cancer, and non-small cell lung cancer (NSCLC). Slate is an \"off the shelf\" immunotherapy targeting solid tumors with select KRAS mutations.\nIf Pfizer acquired Gritstone, the company would pick up two promising cancer immunotherapy candidates. It would gain a COVID vaccine candidate that could be ideal for battling emerging variants. The company would also add a platform that could enable it to more effectively develop a stable of new drugs targeting a variety of diseases.\nBigger targets in sight?\nIt's entirely possible that Pfizer could choose to buy a much larger drugmaker that would immediately boost its revenue and earnings. The company could afford to do so with its fast-growing cash stockpile.\nBut my view is that deals along the lines of the Trillium acquisition are a better use of Pfizer's money. The company should be able to deliver strong growth at least through 2025. Spending less now to gobble up smaller biotechs that could pay off after that point appears to be a smart game plan.\nI think an acquisition of Gritstone by Pfizer could fit quite nicely with such a strategy. And it could make the big pharma stock a bigger winner over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815880908,"gmtCreate":1630665484204,"gmtModify":1676530370263,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"Today no movement&nbsp;","listText":"Today no movement&nbsp;","text":"Today no movement","images":[{"img":"https://static.tigerbbs.com/e4d031426a6b4d853ec8a1d72c52f1b9","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815880908","isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815880008,"gmtCreate":1630665460404,"gmtModify":1676530370262,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"Cfm can invest&nbsp;","listText":"Cfm can invest&nbsp;","text":"Cfm can invest","images":[{"img":"https://static.tigerbbs.com/2473d4ae86cdcd8f643ec9624b409d5b","width":"720","height":"2201"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815880008","isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":812325484,"gmtCreate":1630555110848,"gmtModify":1676530339375,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"I will buy","listText":"I will buy","text":"I will buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812325484","repostId":"1176826510","repostType":4,"repost":{"id":"1176826510","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630552942,"share":"https://ttm.financial/m/news/1176826510?lang=&edition=fundamental","pubTime":"2021-09-02 11:22","market":"us","language":"en","title":"U.S. manufacturing activity rises; shortages linger","url":"https://stock-news.laohu8.com/highlight/detail?id=1176826510","media":"Reuters","summary":"Summary\n\nISM manufacturing index rises 0.4 pts to 59.9 in August.\nNew orders measure increases; empl","content":"<p><b>Summary</b></p>\n<ul>\n <li>ISM manufacturing index rises 0.4 pts to 59.9 in August.</li>\n <li>New orders measure increases; employment gauge contracts.</li>\n <li>Private payrolls increase 374,000 in August.</li>\n</ul>\n<p>WASHINGTON, Sept 1(Reuters) - U.S. manufacturing activity unexpectedly picked up in August amid strong order growth, but a measure of factory employment dropped to a nine-month low, likely as workers remained scarce.</p>\n<p>The survey from the Institute for Supply Management (ISM) on Wednesday continued to highlight persistent problems securing enough raw materials, a situation worsened by disruptions caused by the latest wave of COVID-19 infections, primarily in Southeast Asia, as well as ports congestion in China.</p>\n<p>\"A surprising turn of events for manufacturing activity in the U.S., but it doesn't change the story of supply disruptions and shortages holding back stronger growth,\" said Jennifer Lee, a senior economist at BMO Capital Markets in Toronto.</p>\n<p>The ISM said its index of national factory activity inched up to 59.9 last month from a reading of 59.5 in July. A reading above 50 indicates expansion in manufacturing, which accounts for 11.9% of the U.S. economy. Economists polled by Reuters had forecast the index falling to 58.6.</p>\n<p>Manufacturing is holding up even as spending is rotating back to services from goods because of vaccinations against COVID-19. All of the six largest manufacturing industries, including computer and electronic products, chemical products and transportation equipment reported moderate to strong growth.</p>\n<p>Manufacturers of computer and electronic products said while a global semiconductor shortage was impacting supply lines, they had so far \"been able to manage it without impacting clients.\"</p>\n<p>Chemical goods producers said they continued to \"see extended lead times due to port delays and sea container tightness.\" Transportation equipment makers reported that \"strong sales continue, but production is limited due to supply issues with chips.\"</p>\n<p>The ISM survey's forward-looking new orders sub-index rebounded to a reading of 66.7 last month after two straight monthly declines. Fourteen out of 18 manufacturing industries, furniture and related products, machinery and electrical equipment, appliances and components reported growth in new orders. Only nonmetallic mineral products reported a drop.</p>\n<p>Demand is being driven by businesses desperate to replenish stocks after inventories were drawn down sharply in the first half of the year. Inventory accumulation, which is expected to be the main driver of economic growth for the rest of this year and into 2022, has been frustrated by the supply constraints.</p>\n<p>Stocks on Wall Street were trading higher. The dollar slipped against a basket of currencies. U.S. Treasury prices were mixed.</p>\n<p>Scarce inputs have boosted prices for both manufacturers and consumers. But there appears to be light at the end of the tunnel. The ISM measure of delivery performance of suppliers to manufacturing organizations eased further in August, indicating some improvement in the pace of deliveries.</p>\n<p>The survey's measure of prices paid by manufacturers fell to an eight-month low of 79.4 from a reading of 85.7 in July. This measure has dropped from a record 92.1 in June.</p>\n<p>It was the latest indication that inflation has probably peaked. Data last week showed the Federal Reserve's preferred inflation measure recorded its smallest monthly gain in five months in July.</p>\n<p>But worker shortages persist, with ISM chair Timothy Fiore highlighting \"a clear cycle of labor turnover as workers opt for more attractive job conditions.\"</p>\n<p>A measure of factory employment contracted last month and fell to its lowest level since November.</p>\n<p>Together with the ADP National Employment Report, which showed on Wednesday that private payrolls increased by 374,000 jobs last month after rising 326,000 in July, the ISM factory index poses a downside risk to job growth in August. Economists had forecast the ADP report would show private payrolls increased by 613,000 jobs.read more</p>\n<p>The ADP report is jointly developed with Moody's Analytics and was published ahead of the Labor Department's more comprehensive and closely watched employment report for August on Friday. But it has a dismal record predicting the private payrolls count in the department's Bureau of Labor Statistics (BLS) employment report because of methodology differences.</p>\n<p>According to a Reuters survey of economists, nonfarm payrolls likely increased by 728,000 jobs last month after rising 943,000 in July.</p>\n<p>\"ADP is far from consistent in predicting changes in the BLS payrolls data,\" said Rubeela Farooqi, chief U.S. economist at High Frequency economics in White Plains, New York. \"Overall, job growth has strengthened in recent months, even as companies continue to report labor supply shortages.\"</p>\n<p>The pandemic has upended the labor market dynamics, creating worker shortages even as 8.7 million people are officially unemployed. The were a record 10.1 million job openings at the end of June. Lack of affordable child care, fears of contracting the coronavirus, generous unemployment benefits funded by the federal government as well as pandemic-related retirements and career changes have been blamed for the disconnect.</p>\n<p>The labor shortage is expected to ease starting in September. The government-funded unemployment benefits lapse on Sept. 6 and schools are reopening for in-person learning.</p>\n<p>But the resurgence in new COVID-19 cases, driven by the Delta variant of the coronavirus, could cause reluctance among some people to return to the labor force.</p>\n<p>The labor shortages led to a building up of the backlog of uncompleted work at factories in August.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. manufacturing activity rises; shortages linger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. manufacturing activity rises; shortages linger\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-02 11:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Summary</b></p>\n<ul>\n <li>ISM manufacturing index rises 0.4 pts to 59.9 in August.</li>\n <li>New orders measure increases; employment gauge contracts.</li>\n <li>Private payrolls increase 374,000 in August.</li>\n</ul>\n<p>WASHINGTON, Sept 1(Reuters) - U.S. manufacturing activity unexpectedly picked up in August amid strong order growth, but a measure of factory employment dropped to a nine-month low, likely as workers remained scarce.</p>\n<p>The survey from the Institute for Supply Management (ISM) on Wednesday continued to highlight persistent problems securing enough raw materials, a situation worsened by disruptions caused by the latest wave of COVID-19 infections, primarily in Southeast Asia, as well as ports congestion in China.</p>\n<p>\"A surprising turn of events for manufacturing activity in the U.S., but it doesn't change the story of supply disruptions and shortages holding back stronger growth,\" said Jennifer Lee, a senior economist at BMO Capital Markets in Toronto.</p>\n<p>The ISM said its index of national factory activity inched up to 59.9 last month from a reading of 59.5 in July. A reading above 50 indicates expansion in manufacturing, which accounts for 11.9% of the U.S. economy. Economists polled by Reuters had forecast the index falling to 58.6.</p>\n<p>Manufacturing is holding up even as spending is rotating back to services from goods because of vaccinations against COVID-19. All of the six largest manufacturing industries, including computer and electronic products, chemical products and transportation equipment reported moderate to strong growth.</p>\n<p>Manufacturers of computer and electronic products said while a global semiconductor shortage was impacting supply lines, they had so far \"been able to manage it without impacting clients.\"</p>\n<p>Chemical goods producers said they continued to \"see extended lead times due to port delays and sea container tightness.\" Transportation equipment makers reported that \"strong sales continue, but production is limited due to supply issues with chips.\"</p>\n<p>The ISM survey's forward-looking new orders sub-index rebounded to a reading of 66.7 last month after two straight monthly declines. Fourteen out of 18 manufacturing industries, furniture and related products, machinery and electrical equipment, appliances and components reported growth in new orders. Only nonmetallic mineral products reported a drop.</p>\n<p>Demand is being driven by businesses desperate to replenish stocks after inventories were drawn down sharply in the first half of the year. Inventory accumulation, which is expected to be the main driver of economic growth for the rest of this year and into 2022, has been frustrated by the supply constraints.</p>\n<p>Stocks on Wall Street were trading higher. The dollar slipped against a basket of currencies. U.S. Treasury prices were mixed.</p>\n<p>Scarce inputs have boosted prices for both manufacturers and consumers. But there appears to be light at the end of the tunnel. The ISM measure of delivery performance of suppliers to manufacturing organizations eased further in August, indicating some improvement in the pace of deliveries.</p>\n<p>The survey's measure of prices paid by manufacturers fell to an eight-month low of 79.4 from a reading of 85.7 in July. This measure has dropped from a record 92.1 in June.</p>\n<p>It was the latest indication that inflation has probably peaked. Data last week showed the Federal Reserve's preferred inflation measure recorded its smallest monthly gain in five months in July.</p>\n<p>But worker shortages persist, with ISM chair Timothy Fiore highlighting \"a clear cycle of labor turnover as workers opt for more attractive job conditions.\"</p>\n<p>A measure of factory employment contracted last month and fell to its lowest level since November.</p>\n<p>Together with the ADP National Employment Report, which showed on Wednesday that private payrolls increased by 374,000 jobs last month after rising 326,000 in July, the ISM factory index poses a downside risk to job growth in August. Economists had forecast the ADP report would show private payrolls increased by 613,000 jobs.read more</p>\n<p>The ADP report is jointly developed with Moody's Analytics and was published ahead of the Labor Department's more comprehensive and closely watched employment report for August on Friday. But it has a dismal record predicting the private payrolls count in the department's Bureau of Labor Statistics (BLS) employment report because of methodology differences.</p>\n<p>According to a Reuters survey of economists, nonfarm payrolls likely increased by 728,000 jobs last month after rising 943,000 in July.</p>\n<p>\"ADP is far from consistent in predicting changes in the BLS payrolls data,\" said Rubeela Farooqi, chief U.S. economist at High Frequency economics in White Plains, New York. \"Overall, job growth has strengthened in recent months, even as companies continue to report labor supply shortages.\"</p>\n<p>The pandemic has upended the labor market dynamics, creating worker shortages even as 8.7 million people are officially unemployed. The were a record 10.1 million job openings at the end of June. Lack of affordable child care, fears of contracting the coronavirus, generous unemployment benefits funded by the federal government as well as pandemic-related retirements and career changes have been blamed for the disconnect.</p>\n<p>The labor shortage is expected to ease starting in September. The government-funded unemployment benefits lapse on Sept. 6 and schools are reopening for in-person learning.</p>\n<p>But the resurgence in new COVID-19 cases, driven by the Delta variant of the coronavirus, could cause reluctance among some people to return to the labor force.</p>\n<p>The labor shortages led to a building up of the backlog of uncompleted work at factories in August.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176826510","content_text":"Summary\n\nISM manufacturing index rises 0.4 pts to 59.9 in August.\nNew orders measure increases; employment gauge contracts.\nPrivate payrolls increase 374,000 in August.\n\nWASHINGTON, Sept 1(Reuters) - U.S. manufacturing activity unexpectedly picked up in August amid strong order growth, but a measure of factory employment dropped to a nine-month low, likely as workers remained scarce.\nThe survey from the Institute for Supply Management (ISM) on Wednesday continued to highlight persistent problems securing enough raw materials, a situation worsened by disruptions caused by the latest wave of COVID-19 infections, primarily in Southeast Asia, as well as ports congestion in China.\n\"A surprising turn of events for manufacturing activity in the U.S., but it doesn't change the story of supply disruptions and shortages holding back stronger growth,\" said Jennifer Lee, a senior economist at BMO Capital Markets in Toronto.\nThe ISM said its index of national factory activity inched up to 59.9 last month from a reading of 59.5 in July. A reading above 50 indicates expansion in manufacturing, which accounts for 11.9% of the U.S. economy. Economists polled by Reuters had forecast the index falling to 58.6.\nManufacturing is holding up even as spending is rotating back to services from goods because of vaccinations against COVID-19. All of the six largest manufacturing industries, including computer and electronic products, chemical products and transportation equipment reported moderate to strong growth.\nManufacturers of computer and electronic products said while a global semiconductor shortage was impacting supply lines, they had so far \"been able to manage it without impacting clients.\"\nChemical goods producers said they continued to \"see extended lead times due to port delays and sea container tightness.\" Transportation equipment makers reported that \"strong sales continue, but production is limited due to supply issues with chips.\"\nThe ISM survey's forward-looking new orders sub-index rebounded to a reading of 66.7 last month after two straight monthly declines. Fourteen out of 18 manufacturing industries, furniture and related products, machinery and electrical equipment, appliances and components reported growth in new orders. Only nonmetallic mineral products reported a drop.\nDemand is being driven by businesses desperate to replenish stocks after inventories were drawn down sharply in the first half of the year. Inventory accumulation, which is expected to be the main driver of economic growth for the rest of this year and into 2022, has been frustrated by the supply constraints.\nStocks on Wall Street were trading higher. The dollar slipped against a basket of currencies. U.S. Treasury prices were mixed.\nScarce inputs have boosted prices for both manufacturers and consumers. But there appears to be light at the end of the tunnel. The ISM measure of delivery performance of suppliers to manufacturing organizations eased further in August, indicating some improvement in the pace of deliveries.\nThe survey's measure of prices paid by manufacturers fell to an eight-month low of 79.4 from a reading of 85.7 in July. This measure has dropped from a record 92.1 in June.\nIt was the latest indication that inflation has probably peaked. Data last week showed the Federal Reserve's preferred inflation measure recorded its smallest monthly gain in five months in July.\nBut worker shortages persist, with ISM chair Timothy Fiore highlighting \"a clear cycle of labor turnover as workers opt for more attractive job conditions.\"\nA measure of factory employment contracted last month and fell to its lowest level since November.\nTogether with the ADP National Employment Report, which showed on Wednesday that private payrolls increased by 374,000 jobs last month after rising 326,000 in July, the ISM factory index poses a downside risk to job growth in August. Economists had forecast the ADP report would show private payrolls increased by 613,000 jobs.read more\nThe ADP report is jointly developed with Moody's Analytics and was published ahead of the Labor Department's more comprehensive and closely watched employment report for August on Friday. But it has a dismal record predicting the private payrolls count in the department's Bureau of Labor Statistics (BLS) employment report because of methodology differences.\nAccording to a Reuters survey of economists, nonfarm payrolls likely increased by 728,000 jobs last month after rising 943,000 in July.\n\"ADP is far from consistent in predicting changes in the BLS payrolls data,\" said Rubeela Farooqi, chief U.S. economist at High Frequency economics in White Plains, New York. \"Overall, job growth has strengthened in recent months, even as companies continue to report labor supply shortages.\"\nThe pandemic has upended the labor market dynamics, creating worker shortages even as 8.7 million people are officially unemployed. The were a record 10.1 million job openings at the end of June. Lack of affordable child care, fears of contracting the coronavirus, generous unemployment benefits funded by the federal government as well as pandemic-related retirements and career changes have been blamed for the disconnect.\nThe labor shortage is expected to ease starting in September. The government-funded unemployment benefits lapse on Sept. 6 and schools are reopening for in-person learning.\nBut the resurgence in new COVID-19 cases, driven by the Delta variant of the coronavirus, could cause reluctance among some people to return to the labor force.\nThe labor shortages led to a building up of the backlog of uncompleted work at factories in August.","news_type":1},"isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812325830,"gmtCreate":1630555086520,"gmtModify":1676530339366,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"No surprise today&nbsp;","listText":"No surprise today&nbsp;","text":"No surprise today","images":[{"img":"https://static.tigerbbs.com/e4d031426a6b4d853ec8a1d72c52f1b9","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812325830","isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":812322391,"gmtCreate":1630555000813,"gmtModify":1676530339172,"author":{"id":"3582448988391909","authorId":"3582448988391909","name":"HauSG","avatar":"https://static.tigerbbs.com/d69d0532d6f1ac04316e70c1166f0acd","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582448988391909","authorIdStr":"3582448988391909"},"themes":[],"htmlText":"Nice story&nbsp;","listText":"Nice story&nbsp;","text":"Nice story","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812322391","repostId":"2164481914","repostType":4,"repost":{"id":"2164481914","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630529217,"share":"https://ttm.financial/m/news/2164481914?lang=&edition=fundamental","pubTime":"2021-09-02 04:46","market":"us","language":"en","title":"Tech stocks send Nasdaq to fresh record close, boost S&P","url":"https://stock-news.laohu8.com/highlight/detail?id=2164481914","media":"Reuters","summary":"Gains for tech stocks, utilities and real estate.\nAugust private jobs growth misses expectations.\nIn","content":"<ul>\n <li>Gains for tech stocks, utilities and real estate.</li>\n <li>August private jobs growth misses expectations.</li>\n <li>Indexes: Dow falls 0.14%, S&amp;P up 0.03%, Nasdaq rises 0.33%.</li>\n</ul>\n<p>Sept 1 (Reuters) - The Nasdaq closed Wednesday at a record high, and the S&amp;P 500 rose but just missed a fresh peak, as September kicked off with renewed buying of technology stocks and private payrolls data, which supported the case for dovish monetary policy.</p>\n<p>Technology stocks , which tend to benefit from a low-rate environment, finished higher. Apple Inc rose 0.4% to its second-highest close, and <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc , Amazon.com Inc and Google-owner Alphabet Inc all advanced between 0.2% and 0.7%.</p>\n<p>Utilities and real estate - sectors considered as bond-proxies or defensive - were the top performers.</p>\n<p>\"Given there's going to be some choppiness in the economic recovery because of COVID, people will look for where they can find the best future growth potential,\" said Chris Graff, co-chief investment officer at RMB Capital.</p>\n<p>Wall Street's main indexes have hit record highs recently, with the benchmark S&amp;P 500 notching seven straight monthly gains as investors shrugged off risks around a rise in new coronavirus infections and hoped for the Fed to remain dovish in its policy stance.</p>\n<p>Each new data release though is viewed by investors through the prism of whether it could push the Fed to taper sooner rather than later.</p>\n<p>A report by ADP, published ahead of the U.S. government's more comprehensive employment report on Friday, showed private employers hired far fewer workers than expected in August.</p>\n<p>Another set of data on Wednesday showed U.S. manufacturing activity unexpectedly picked up in August amid strong order growth, but a measure of factory employment dropped to a nine-month low, likely as workers remained scarce.</p>\n<p>\"We've got the jobs report on Friday, but what's become more important is the job openings report next week and the CPI release after that, so a lot about employment and inflation in the next couple of weeks which will reset people's expectations for tapering and interest rates,\" Graff added.</p>\n<p>The Dow Jones Industrial Average fell 48.2 points, or 0.14%, to 35,312.53, the S&amp;P 500 gained 1.41 points, or 0.03%, to 4,524.09 and the Nasdaq Composite added 50.15 points, or 0.33%, to 15,309.38.</p>\n<p>Falling 1.5% on the day, and down for the third straight session, was the energy index.</p>\n<p>Crude prices were flat after OPEC and its allies agreed to stick to their existing policy of gradual output increases. However, the full extent of damage to U.S. energy infrastructure from Hurricane Ida is still being established&nbsp;More than 80% of oil and gas production in the Gulf of Mexico remains offline, while analysts have warned that restarting Louisiana refineries shut by the storm could take weeks and cost operators tens of millions of dollars in lost revenue.</p>\n<p><a href=\"https://laohu8.com/S/PBF\">PBF Energy</a> Inc , whose 190,000 barrel-per-day Chalmette, Louisiana, refinery lost power following the storm, slumped 6.8% on Wednesday, taking its losses this week to 11.2%.</p>\n<p>Volume on U.S. exchanges was 9.81 billion shares, compared with the 8.99 billion average for the full session over the last 20 trading days.</p>\n<p>The S&amp;P 500 posted 55 new 52-week highs and no new lows; the Nasdaq Composite recorded 131 new highs and 17 new lows.</p>\n<p>(Reporting by Shashank Nayar in Bengaluru and David French in New York; Editing by Aditya Soni and Lisa Shumaker)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech stocks send Nasdaq to fresh record close, boost S&P</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech stocks send Nasdaq to fresh record close, boost S&P\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-02 04:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Gains for tech stocks, utilities and real estate.</li>\n <li>August private jobs growth misses expectations.</li>\n <li>Indexes: Dow falls 0.14%, S&amp;P up 0.03%, Nasdaq rises 0.33%.</li>\n</ul>\n<p>Sept 1 (Reuters) - The Nasdaq closed Wednesday at a record high, and the S&amp;P 500 rose but just missed a fresh peak, as September kicked off with renewed buying of technology stocks and private payrolls data, which supported the case for dovish monetary policy.</p>\n<p>Technology stocks , which tend to benefit from a low-rate environment, finished higher. Apple Inc rose 0.4% to its second-highest close, and <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc , Amazon.com Inc and Google-owner Alphabet Inc all advanced between 0.2% and 0.7%.</p>\n<p>Utilities and real estate - sectors considered as bond-proxies or defensive - were the top performers.</p>\n<p>\"Given there's going to be some choppiness in the economic recovery because of COVID, people will look for where they can find the best future growth potential,\" said Chris Graff, co-chief investment officer at RMB Capital.</p>\n<p>Wall Street's main indexes have hit record highs recently, with the benchmark S&amp;P 500 notching seven straight monthly gains as investors shrugged off risks around a rise in new coronavirus infections and hoped for the Fed to remain dovish in its policy stance.</p>\n<p>Each new data release though is viewed by investors through the prism of whether it could push the Fed to taper sooner rather than later.</p>\n<p>A report by ADP, published ahead of the U.S. government's more comprehensive employment report on Friday, showed private employers hired far fewer workers than expected in August.</p>\n<p>Another set of data on Wednesday showed U.S. manufacturing activity unexpectedly picked up in August amid strong order growth, but a measure of factory employment dropped to a nine-month low, likely as workers remained scarce.</p>\n<p>\"We've got the jobs report on Friday, but what's become more important is the job openings report next week and the CPI release after that, so a lot about employment and inflation in the next couple of weeks which will reset people's expectations for tapering and interest rates,\" Graff added.</p>\n<p>The Dow Jones Industrial Average fell 48.2 points, or 0.14%, to 35,312.53, the S&amp;P 500 gained 1.41 points, or 0.03%, to 4,524.09 and the Nasdaq Composite added 50.15 points, or 0.33%, to 15,309.38.</p>\n<p>Falling 1.5% on the day, and down for the third straight session, was the energy index.</p>\n<p>Crude prices were flat after OPEC and its allies agreed to stick to their existing policy of gradual output increases. However, the full extent of damage to U.S. energy infrastructure from Hurricane Ida is still being established&nbsp;More than 80% of oil and gas production in the Gulf of Mexico remains offline, while analysts have warned that restarting Louisiana refineries shut by the storm could take weeks and cost operators tens of millions of dollars in lost revenue.</p>\n<p><a href=\"https://laohu8.com/S/PBF\">PBF Energy</a> Inc , whose 190,000 barrel-per-day Chalmette, Louisiana, refinery lost power following the storm, slumped 6.8% on Wednesday, taking its losses this week to 11.2%.</p>\n<p>Volume on U.S. exchanges was 9.81 billion shares, compared with the 8.99 billion average for the full session over the last 20 trading days.</p>\n<p>The S&amp;P 500 posted 55 new 52-week highs and no new lows; the Nasdaq Composite recorded 131 new highs and 17 new lows.</p>\n<p>(Reporting by Shashank Nayar in Bengaluru and David French in New York; Editing by Aditya Soni and Lisa Shumaker)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164481914","content_text":"Gains for tech stocks, utilities and real estate.\nAugust private jobs growth misses expectations.\nIndexes: Dow falls 0.14%, S&P up 0.03%, Nasdaq rises 0.33%.\n\nSept 1 (Reuters) - The Nasdaq closed Wednesday at a record high, and the S&P 500 rose but just missed a fresh peak, as September kicked off with renewed buying of technology stocks and private payrolls data, which supported the case for dovish monetary policy.\nTechnology stocks , which tend to benefit from a low-rate environment, finished higher. Apple Inc rose 0.4% to its second-highest close, and Facebook Inc , Amazon.com Inc and Google-owner Alphabet Inc all advanced between 0.2% and 0.7%.\nUtilities and real estate - sectors considered as bond-proxies or defensive - were the top performers.\n\"Given there's going to be some choppiness in the economic recovery because of COVID, people will look for where they can find the best future growth potential,\" said Chris Graff, co-chief investment officer at RMB Capital.\nWall Street's main indexes have hit record highs recently, with the benchmark S&P 500 notching seven straight monthly gains as investors shrugged off risks around a rise in new coronavirus infections and hoped for the Fed to remain dovish in its policy stance.\nEach new data release though is viewed by investors through the prism of whether it could push the Fed to taper sooner rather than later.\nA report by ADP, published ahead of the U.S. government's more comprehensive employment report on Friday, showed private employers hired far fewer workers than expected in August.\nAnother set of data on Wednesday showed U.S. manufacturing activity unexpectedly picked up in August amid strong order growth, but a measure of factory employment dropped to a nine-month low, likely as workers remained scarce.\n\"We've got the jobs report on Friday, but what's become more important is the job openings report next week and the CPI release after that, so a lot about employment and inflation in the next couple of weeks which will reset people's expectations for tapering and interest rates,\" Graff added.\nThe Dow Jones Industrial Average fell 48.2 points, or 0.14%, to 35,312.53, the S&P 500 gained 1.41 points, or 0.03%, to 4,524.09 and the Nasdaq Composite added 50.15 points, or 0.33%, to 15,309.38.\nFalling 1.5% on the day, and down for the third straight session, was the energy index.\nCrude prices were flat after OPEC and its allies agreed to stick to their existing policy of gradual output increases. However, the full extent of damage to U.S. energy infrastructure from Hurricane Ida is still being established More than 80% of oil and gas production in the Gulf of Mexico remains offline, while analysts have warned that restarting Louisiana refineries shut by the storm could take weeks and cost operators tens of millions of dollars in lost revenue.\nPBF Energy Inc , whose 190,000 barrel-per-day Chalmette, Louisiana, refinery lost power following the storm, slumped 6.8% on Wednesday, taking its losses this week to 11.2%.\nVolume on U.S. exchanges was 9.81 billion shares, compared with the 8.99 billion average for the full session over the last 20 trading days.\nThe S&P 500 posted 55 new 52-week highs and no new lows; the Nasdaq Composite recorded 131 new highs and 17 new lows.\n(Reporting by Shashank Nayar in Bengaluru and David French in New York; Editing by Aditya Soni and Lisa Shumaker)","news_type":1},"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}